State of the Russian Oncology Service: lip cancer. Population-based study at the federal district level. Part II. Survival of patients, median of survival, survival of patients taking into account the localization, histological structure and disease stage

Cover Page

Cite item

Full Text

Abstract

Malignant neoplasms of the lip are a rare type of tumor. State reporting provides only a set of data for calculating incidence rates. The Population-Based Cancer Registry (PCR) database developed by us at the level of the Northwestern Federal District of the Russian Federation allowed, for the first time in Russia, to calculate a set of analytical indicators, such as the median survival, one-year and five-year cumulative survival rates of lip cancer patients, taking into account the detailed localization and histological structure.

The aim of the study was to investigate the level and trends in survival of lip cancer patients in the Northwestern Federal District of the Russian Federation considering the localization and histological structures and the stage of the disease.

The material of the study was the Population-based Cancer Registry of the Northwestern Federal District of the Russian Federation. Data processing was carried out using the methodology recommended by the International Association of Cancer Registries under the EUROCARE program.

Unfavorable trends in the lip cancer incidence rate have been established in Russia and the Northwestern Federal District of the Russian Federation. The median survival remained within 6–8 years. Survival rates of patients have indicated a high level of treatment of patients with malignant lip neoplasms at the level of the Northwestern Federal District. Survival of patients in the first year of observation was: observed – 89.3%, relative – 93.8%. The five-year observed survival did not reach 50%, the relative exceeded 60%.

Detailed localization development of the PCR data has revealed that patients with malignant neoplasms of the outer surface of the lower lip (C00.1) account for 60%. Histological characteristics of the registered patients have been significantly improved.

About the authors

Vakhtang M. Merabishvili

N.N. Petrov National Medical Research Center of Oncology

Author for correspondence.
Email: MVM@niioncologii.ru
ORCID iD: 0000-0002-1521-455X
SPIN-code: 5705-6327

Doctor of Medicine (MD), Professor, Chief of the Oncological Statistics Scientific Laboratory, Chairman of the Scientific-Methodological Council on the Development of Information Systems of Cancer Control of the Northwestern Federal District; Head of the Population-based Cancer Registry of the Northwestern Federal District of the Russian Federation

Russian Federation, St. Petersburg

Alexander B. Vasilyev

Saint Petersburg Regional Charitable Foundation “Cancer Prevention”

Email: 5849898@bk.ru

Chief Medical Officer

Russian Federation, Saint Petersburg

Elvira N. Merabishvili

North-Western State Medical University named after I.I. Mechnikov of the Healthcare Ministry of the Russian Federation

Email: MVM@niioncologii.ru

Ph.D. in Medicine, Senior Lecturer, Department of Human Morphology

Russian Federation, Saint Petersburg

Alexey F. Barsukov

North-Western State Medical University named after I.I. Mechnikov of the Healthcare Ministry of the Russian Federation

Email: MVM@niioncologii.ru
SPIN-code: 9221-8063

Ph.D. in Medicine, Doctor of the highest qualification category, Department of Otorhinolaryngology (ENT), Clinic named after Peter the Great

Russian Federation, Saint Petersburg

References

  1. Merabishvili V. M. Malignant cardiac tumors – rare, but dangerous tumors (based on the data obtained in the Northwestern Federal District of Russia). Formuly Farmacii = Pharmacy Formulas. 2020;2(3):30-39. (In Russ.).
  2. Merabishvili V. M., Merabishvili E. N. The Prevalence of Malignant Tumors of the Eye and Adnexa (C69). Oftal’mologija = Ophthalmology in Russia. 2020;17(3):495–501. (In Russ.).
  3. Merabishvili V. M., Merabishvili E. N. Age-related features of the prevalence and survival of patients with malignant tumors of the eye and its adnexa (C69) with taking into account the localization and histological structure: Population study. Uspehi gerontologii = Adv Gerontol. 2020;33(3):561–568. (In Russ.).
  4. Merabishvili V. M., Shcherbuk Yu. A., eds. Survival of cancer patients. 2nd issue. Part II. Saint Petersburg: KOSTA; 2011. 408 p. (In Russ.).
  5. Merabishvili V. M., ed. Spravochnik sopostavleniya kodov MKB-9 i MKB-10 peresmotrov po klassu novoobrazovanij. Second edition, revised and expanded. Saint Petersburg; 1998. 91 p. (In Russ.).
  6. Beljaev A. M., Chepik O. F., Artem’eva A. S., et al., eds. Mezhdunarodnaja klassifikacija boleznej – onkologija (MKB-O), 3 izdanie, 1 peresmotr. Sost. Je. Fritc, K. Persi, Je. Dzhek, K. Shanmugaratnam, L. Sobin, D.M. Parkin, Sh. Uilan. Saint Petersburg: Voprosy onkologii; 2017. 352 p. (In Russ.).
  7. Merabishvili V. M., Shcherbuk Yu. A., eds. Survival of cancer patients. 2nd issue. Part II. Saint Petersburg: KOSTA; 2011. 408 p. (In Russ.).
  8. Merabishvili V. M., ed. Malignant tumors in Saint Petersburg (analysis of cancer registry database according to international standards: morbidity, mortality, survival). Saint Petersburg: Ladoga; 2015. 297 p. (In Russ.).
  9. Merabishvili V. M., Belyaev A. M., eds. Malignant tumors in the NorthWest Federal Region of Russia (morbidity, mortality, prevalence rate, survival). Express-information. 4th issue. Guidelines for physicians. Saint Petersburg: T8 Print; 2018. 444 p. (In Russ.).
  10. Berezkin D. P. Metody izucheniya vyzhivaemosti onkologicheskih bol’nyh. Leningrad; 1982. 19 p. (In Russ.).
  11. Merabishvili V. M., ed. Medical-statistical terminological glossary methodical manual for physicians, residents, graduate students and researchers. The second edition, supplemented by terms, illustrations and the author’s comments. Moscow: T8 Publishing Technologies; 2021. 120 p. (In Russ.).
  12. Merabishvili V. M., ed. ONCOLOGICAL STATISTICS (traditional methods, new information technologies). Guidelines for physicians. Part I. Saint Petersburg: KOSTA; 2011. 221 p. (In Russ.).
  13. Merabishvili V. M., ed. ONCOLOGICAL STATISTICS (traditional methods, new information technologies). Guidelines for physicians. Part II. Saint Petersburg: KOSTA; 2011. 248 p. (In Russ.).
  14. Napalkov N. P., Berezkin D. P. Principy i metody izucheniya vyzhivaemosti onkologicheskih bol’nyh. Voprosy onkologii=Problems in oncology. 1982;(8):10-13. (In Russ.).
  15. Berrino F., Capocaccia R., Esteve J., et al. EUROCARE-3: the survival of cancer patients diagnosed in Europe during 1990-94. Ann Oncol. 2003;14(Suppl. 5):1–155.
  16. Capocaccia R., Gavin A., Hakulinen T., et al. Survival of cancer patients in Europe, 1995-2002. The EUROCARE-4 study. Eur J Cancer. 2009;45(6):992–1005.
  17. De Angelis R., Sant M., Coleman M., et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5–a population-based study. Lancet Oncol. 2014;15:23-34.
  18. Gatta G., Botta L., Rossi S., et al. Childhood cancer survival in Europe 1997-2007: results of EUROCARE-5-a population-based study. Lancet Oncol. 2014;15:35–47.
  19. Vazhenin A., Domozhirova A., Aksenova I., et al. Cancer incidence in Russian Federation, Chelyabinsk // Bray F., Colombet M., L. Mery L., et al., eds. IARC Sci. Publ. No. 166. Cancer incidence in Five Continents. Vol. XI. Lyon, France: IARC; 2021. 1545 p.
  20. Kaprin A. D., Starinsky V. V., Shakhzadova A. O., eds. State of oncological care in Russia in 2019. Moscow: P. A. Herzen Moscow State Medical Research Institute – branch of the NMRRC of the Ministry of Health of the Russian Federation; 2020. 239 p. (In Russ.).

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Trends in cumulative observed 5-year survival of lip cancer patients considering disease stage (both sexes). NWFD RF PCR database

Download (643KB)
Indexing metadata

Copyright (c) 2021 Merabishvili V.M., Vasilyev A.B., Merabishvili E.N., Barsukov A.F.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies